RxDoctor Payments Data

Jessica Prisco, NP

Primary Care · Norwich, CTNPI 1407300593

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $290 of the $402 with a category attached, or 72.0%. 9 manufacturers reported payments, led by Medtronic at 32.7% of the total.

$402in general payments, 2019–2025

Across 18 payments — averaging $22.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$132
  • AstraZeneca$69
  • Novartis$33
  • E.r. Squibb & Sons, L.L.C.$32
  • Boehringer Ingelheim$31
  • Baxter Healthcare$28
  • plus $78 from 3 others

What the payments were for

  • Food & beverage$29072%
  • Education$11328%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$402 in reported general payments places this provider in the 55th percentile of 111 primary care providers in Connecticut.

See all primary care providers in Connecticut

Medicare billing

Part B allowed, 2024
$40,404
Medicare patients
221
Services billed
324

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban147$197,105
JardianceEmpagliflozin88$92,740
EntrestoSacubitril/Valsartan58$76,276
XareltoRivaroxaban28$29,335
BrilintaTicagrelor19$24,103
FarxigaDapagliflozin Propanediol12$15,772
Metoprolol Succinate218$2,629
Dofetilide14$2,161
Ranolazine ErRanolazine22$2,100
Atorvastatin Calcium185$1,961
Rosuvastatin Calcium115$1,388
Ezetimibe47$1,343
Carvedilol135$1,278
Furosemide186$1,007
Diltiazem 24hr Er (Cd)Diltiazem Hcl47$1,005

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$27$197,105147 claims
Boehringer IngelheimJardiance$31$92,74088 claims
NovartisEntresto$33$76,27658 claims
AstraZenecaBrilinta, Farxiga$69$39,87531 claims
Johnson & JohnsonXarelto$26$29,33528 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 111 primary care providers in Connecticut.

Other primary care in Norwich

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →